Recent advances in Alzheimer’s disease treatment are offering new hope to patients and their families, though expectations need careful calibration: the latest medications approved for early-stage Alzheimer’s show promise in slowing cognitive decline, not in fully restoring lost memory function. Lecanemab (marketed as Leqembi) and donanemab represent a shift in how doctors approach the disease, targeting amyloid buildup in the brain rather than just managing symptoms like a traditional Alzheimer’s drug would. For patients in early stages of cognitive decline or mild cognitive impairment, these medications have demonstrated measurable delays in memory deterioration, which can mean months or even years of maintained independence.
The difference between slowing decline and restoration is crucial to understand. When a patient’s memory has significantly deteriorated, these new medications cannot reverse that damage or restore function that’s already been lost. Instead, they work on a different principle: they aim to slow the pace at which memory and cognitive abilities decline. For someone diagnosed early—before substantial memory loss occurs—this can mean preserving the ability to manage finances, remember family members, and live independently for a longer period.
Table of Contents
- What Are These New Memory-Focused Alzheimer’s Medications?
- How Do These New Medications Address Memory Loss?
- What Real-World Results Can Patients Actually Expect?
- Who Is Eligible for These Breakthrough Treatments?
- What Are the Significant Limitations and Risks?
- The Practical Treatment Process and What Ongoing Monitoring Involves
- What Emerging Treatments Are in Development?
What Are These New Memory-Focused Alzheimer’s Medications?
The medications approved in recent years represent a major change in Alzheimer’s treatment strategy. Lecanemab became the first disease-modifying Alzheimer’s drug to gain full FDA approval, with donanemab following. Both work by targeting amyloid-beta, a protein that accumulates in the brains of Alzheimer’s patients and is believed to contribute to neurodegeneration. Rather than just masking symptoms, these medications attempt to address what many researchers believe is a root cause of cognitive decline. How these medications differ from older Alzheimer’s drugs is significant.
Drugs like donepezil (Aricept) and rivastigmine (Exelon) were designed to preserve the function of remaining brain cells by preventing the breakdown of acetylcholine, a neurotransmitter. They provided modest symptomatic improvement and worked for many patients. The new amyloid-targeting medications take a different approach entirely: they remove or prevent amyloid from accumulating, theoretically stopping the disease process earlier. For context, consider a comparison: traditional Alzheimer’s drugs are like putting a higher-powered battery in a deteriorating clock to keep it running a bit longer. The new medications are more like removing the gunk that’s damaging the clock’s mechanisms before too much harm occurs. This explains why timing matters so much with these newer treatments.
How Do These New Medications Address Memory Loss?
Lecanemab works by helping the immune system clear amyloid-beta plaques from the brain. It’s given as an intravenous infusion every two weeks, and it requires ongoing monitoring because of potential side effects. The mechanism is elegant in theory: remove the protein that’s causing damage, and you stop the disease progression. In practice, clinical trials showed that patients who received the medication experienced slower cognitive decline compared to placebo, but the decline still happened—it was just delayed. A critical limitation that patients and families must understand: amyloid accumulation begins years before memory problems appear. Once cognitive symptoms are noticeable, significant brain damage has usually already occurred.
This is why these medications work best when given early, before major memory loss develops. For patients with moderate to severe dementia, these medications offer little benefit because the underlying damage is extensive. The window of opportunity is genuinely narrow—those with mild cognitive impairment or early dementia due to Alzheimer’s disease pathology. Donanemab operates on a similar principle but with a different mechanism: instead of clearing amyloid plaques, it targets amyloid-beta protofibrils, which are thought to be especially toxic forms of the protein. Early data suggested it might slow decline more effectively than lecanemab, but it also carries similar risks and limitations. Neither medication can currently restore lost cognitive function, and both require careful monitoring by neurologists and geriatricians.
What Real-World Results Can Patients Actually Expect?
Clinical trial data showed that lecanemab slowed cognitive decline by approximately one-third to one-half compared to placebo over 18 months in early-stage patients. That translates to a delay—patients in the treatment group declined more slowly, but they did still decline. Some patients preserved cognitive function that would otherwise have been lost during that period. For someone at risk of progressing from mild cognitive impairment to early-stage dementia, this delay can be meaningful. The variability in outcomes is important to acknowledge. Not every patient responds equally. Some show measurable slowing of decline; others show little to no benefit.
There’s currently no reliable way to predict who will respond well before starting the medication. This unpredictability means patients must commit to ongoing treatment, regular monitoring, and the inconvenience of biweekly infusions without guaranteed results. Side effects also play a role in what patients experience. Amyloid-related imaging abnormalities (ARIA) can occur, including brain microhemorrhages or brain microinfarcts. While these are often asymptomatic, they require ongoing MRI monitoring to detect. Some patients experience headaches, confusion, or visual disturbances. For elderly patients with other health conditions, the burden of treatment can outweigh the modest cognitive benefits, and treatment may need to be stopped.
Who Is Eligible for These Breakthrough Treatments?
These medications are approved specifically for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease who also have confirmed amyloid pathology in the brain. Confirmation requires either a PET scan or cerebrospinal fluid analysis—not all patients with cognitive decline have Alzheimer’s-related amyloid buildup, so diagnostic testing is essential before beginning treatment. This specificity means the medication won’t help patients whose cognitive problems stem from vascular disease, Lewy body dementia, frontotemporal dementia, or other causes. Age and overall health are practical considerations. These medications are intravenous infusions requiring biweekly visits to an infusion center for months or years. Patients must be cognitively aware enough to participate in regular monitoring and report side effects.
They need reliable transportation and family support. For frail elderly patients or those with significant comorbidities, the burden of treatment logistics may make it impractical despite potential benefit. Insurance coverage and access represent another practical barrier. While Medicare covers lecanemab under certain conditions, not all insurance plans provide coverage for donanemab. Out-of-pocket costs can be substantial, and geographic access to centers equipped for regular amyloid-targeted infusions may be limited in rural areas. This means that while these medications exist and show promise, not all patients who might benefit can easily access them.
What Are the Significant Limitations and Risks?
The most important limitation is that these medications cannot restore memory that’s already been lost. If someone has progressed to moderate dementia where substantial cognitive damage has occurred, these treatments will not reverse that damage or restore lost abilities. They’re tools for slowing decline in early disease, not cures and not memory-restoration therapies. Families sometimes misunderstand marketing or hope-driven descriptions and expect these medications to help a family member whose severe dementia is already well-established—and this can lead to disappointment and inappropriate treatment decisions. Amyloid-related imaging abnormalities (ARIA) are a genuine safety concern that requires ongoing vigilance. Microhemorrhages in the brain, while usually asymptomatic, theoretically increase stroke risk. Some patients have experienced cognitive worsening associated with these abnormalities.
MRI screening needs to occur before treatment and regularly during treatment. For patients who develop ARIA, the medication must often be stopped, reversing any benefit gained. Individuals with certain genetic risk factors (particularly those carrying the APOE4 gene) may face higher ARIA risk, though treatment isn’t automatically contraindicated. Another limitation is that Alzheimer’s disease is not purely an amyloid disease. Tau tangles, neuroinflammation, and other pathologic processes also drive neurodegeneration. Removing amyloid addresses one piece of a complex puzzle. As patients progress and tau tangles become more prominent, amyloid-targeted treatments become less effective. This explains why these medications work best very early and why their benefit plateaus over time.
The Practical Treatment Process and What Ongoing Monitoring Involves
Patients approved for lecanemab or donanemab begin with a loading phase: lecanemab requires 11 biweekly infusions to reach therapeutic dose, then continues at maintenance dosing. Each infusion session takes several hours. Before starting and throughout treatment, patients undergo MRI screening to detect asymptomatic brain microhemorrhages. Cognitive testing is repeated periodically to measure whether decline is actually slowing.
Blood tests monitor for any systemic effects. The commitment is substantial and often underestimated by patients hoping these medications might be easier than traditional infusions. Missing infusions interrupts the therapeutic effect. The biweekly schedule persists for years, making it a long-term commitment that requires reliable follow-up care, transportation, and stable living circumstances. Some patients find this sustainable; others find the burden leads them to discontinue treatment despite potential benefit.
What Emerging Treatments Are in Development?
Research continues on other amyloid-targeted approaches, including oral monoclonal antibodies that might be easier to administer than IV infusions. Tau-targeted therapies are also in clinical trials, aimed at addressing the tangles that appear later in Alzheimer’s disease progression. Combination approaches—using multiple medications with different targets simultaneously—are being explored based on the understanding that Alzheimer’s involves multiple pathologic processes.
Preventive approaches are also advancing. Studies are examining whether these disease-modifying medications might prevent or delay cognitive decline in people with amyloid pathology but no symptoms yet. If successful, this could shift Alzheimer’s treatment to a preventive model similar to how statins are used for cardiovascular disease. However, this remains investigational, and widespread preventive screening for asymptomatic amyloid is not yet standard of care.
- —
